Vitreous substitutes as drug release systems;Glaskörperersatz als Möglichkeit zur protrahierten Freisetzung von Medikamenten im Glaskörper

Klinische Monatsblatter fur Augenheilkunde

Volumn 226, Issue 9, 2009, Pages 718-724

  Szurman, P ^a   Frank, C ^a   Kaczmarek, R T ^b   Spitzer, M S ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY OF WROC AW   (Poland)

Author keywords

Pharmacology; Retina; Vitreous

Indexed keywords

ANTIINFLAMMATORY AGENT; CHLORPHENOTANE; CORTICOSTEROID; CYCLINE; DAUNORUBICIN; FLUOROURACIL; LOW MOLECULAR WEIGHT HEPARIN; SILICONE OIL; TRIAMCINOLONE ACETONIDE; TRICHLOROETHANOL;

ADJUVANT THERAPY; CELL PROLIFERATION; DRUG HALF LIFE; DRUG RELEASE; HYDROGEL; MONOTHERAPY; PARS PLANA VITRECTOMY; POLYMERIZATION; REOPERATION; RETINA CELL; REVIEW; VITRECTOMY; VITREORETINOPATHY; VITREOUS BODY;

EID: 77949729454     PISSN: 00232165     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0028-1109653     Document Type: Review

References (41)

1. Araiz J J., Refojo M F., Arroyo M H. et al. Antiproliferative effect of retinoic acid in intravitreous silicone oil in an animal model of proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 1993 34 522-530
2. Arroyo M H., Refojo M F., Araiz J J. et al. Silicone oil as a delivery vehicle for BCNU in rabbit proliferative. etina 1993 13 245-250
3. Asaria R HY, Kon C H., Bunce C et al. Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy: results from a randomized, double-blind, controlled clinical trial. Ophthalmology 2001 108 1179-1183
4. Bambas B, Eckardt C, Vowinkel E et al. Toxische Substanzen im Silikonöl nach intraokularer Injektion. Ophthalmologe 1995 92 663-667
5. Blumenkranz M, Hernandez E, Ophir A et al. 5-fluorouracil: New applications in complicated retinal detachment for an established antimetabolite. Ophthalmology 1984 91 122-130
6. Borhani H, Peyman G A., Rahimy M H. et al. Suppression of experimental proliferative vitreoretinopathy by sustained intraocular delivery of 5-FU. Int Ophthalmol 1995 19 43-49
7. Cardillo J A., Farah M E., Mitre J et al. An intravitreal biodegradable sustained release naproxen and 5-fluorouracil system for the treatment of experimental post-traumatic proliferative vitreoretinopathy. Br J Ophthalmol 2004 88 1201-1205
8. Cavalieri F, Miano F, DAntona P et al. Study of gelling behavior of poly(vinyl alcohol)-methacrylate for potential utilizations in tissue replacement and drug delivery. Biomacromolecules 2004 5 2439-2446
9. Charteris D G. Proliferative vitreoretinopathy: pathobiology, surgical management and adjunctive treatment. Br J Ophthalmol 1995 79 953-960
10. Charteris D G., Aylward G W., Wong D et al. A randomized controlled trial of combined 5-fluorouracil and low-molecular-weight heparin in management of established proliferative vitreoretinopathy. Ophthalmology 2004 111 2240-2245
11. Cheema R A., Peyman G A., Fang T et al. Triamcinolone acetonide as an adjuvant in the surgical treatment of retinal detachment with proliferative vitreoretinopathy. Ophthalmic Surg Lasers Imaging 2007 38 365-370
12. Chirila T V., Hong Y, Dalton P D. et al. The use of hydrophilic polymers as artificial vitreous. Prog Polym Sci 1998 23 475-508
13. Deutschmann R. Ãœber ein neues Heilverfahren bei Netzhautablösung. Zbl Augenheilkunde 1985 19 209-213
14. Fernandez-Vigo J, Refojo M F., Verstraeten T. Evaluation of a viscoelastic solution of hydroxypropyl methylcellulose as a potential vitreous substitute. Retina 1990 10 148-152
15. Frank C, Spitzer M S., Henke-Fahle S et al. Cross-linked biopolymer hyaluronic acid as artificial vitreous substitute. Invest Ophthalmol Vis Sci 2009 50 ARVO E-Abstract 4445
16. Graham R O., Peyman G A. Intravitreal injection of dexamethasone. Treatment of experimentally induced endophthalmitis. Arch Ophthalmol 1974 92 149-154
17. Hegazy H M., Kivilcim M, Peyman G A. et al. Evaluation of toxicity of intravitreal ceftazidime, vancomycin, and ganciclovir in a silicone oil-filled eye. Retina 1999 19 553-557
18. Heimann H, Bartz-Schmidt K U., Bornfeld N et al. Primäre Pars-plana-Vitrektomie. Techniken, Indikationen und Ergebnisse. Ophthalmologe 2008 105 19-26
19. Hong Y, Chirila T V., Vijayasekaran S et al. Biodegradation in vitro and retention in the rabbit eye of crosslinked poly(1-vinyl-2-pyrrolidinone) hydrogel as a vitreous substitute. J Biomed Mater Res 1998 39 650-659
20. Jonas J B., Hayler J K., Panda-Jonas S. Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative vitreoretinopathy. Br J Ophthalmol 2000 84 1064-1067
21. Joussen A M., Wong D. The concept of heavy tamponades-chances and limitations. Graefes Arch Clin Exp Ophthalmol 2008 246 1217-1224
22. Joussen A M., Lux A, Kirchhof B. Shifting of the proliferative vitreoretinopathy milieu after tamponade with heavy silicone oil in eyes prone to proliferative vitreoretinopathy and bleeding. Br J Ophthalmol 2009 93 128-129
23. Koster R, Stilma J S. Healon as intravitreal stubstitute in retinal detachment surgery in 40 patients. Doc Ophthalmol 1986 64 13-17
24. Kralinger M T., Hamasaki D, Kieselbach G F. et al. Intravitreal acetylsalicylic acid in silicone oil: pharmacokinetics and evaluation of its safety by ERG and histology. Graefes Arch Clin Exp Ophthalmol 2001 239 208-216
25. Lewis H, Aaberg T M., Abrams G W. Causes of failure after initial vitreoretinal surgery for severe proliferative vitreoretinopathy. Am J Ophthalmol 1991 111 8-14
26. Lou X, Garrett K L., Rakoczy P E. et al. Synthetic hydrogels as carriers in antisense therapy: preliminary evaluation of an oligodeoxynucleotide covalent conjugate with a copolymer of 1-vinyl-2-pyrrolidinone and 2-hydroxyethyl methacrylate. J Biomater Appl 2001 15 307-320
27. Machemer R, Sugita G, Tano Y. Treatment of intraocular proliferations with intravitreal steroids. Trans Am Ophthalmol Soc 1979 77 171-180
28. Meinert H, Roy T. Semifluorinated alkanes a new class of compounds with outstanding properties for use in ophthalmology. Eur J Ophthalmol 2000 10 189-197
29. Munir W M., Pulido J S., Sharma M C. et al. Intravitreal triamcinolone for treatment of complicated proliferative diabetic retinopathy and proliferative vitreoretinopathy. Can J Ophthalmol 2005 40 598-604
30. Ryan S J. The pathophysiology of proliferative vitreoretinopathy in its management. Am J Ophthalmol 1985 100 188-193
31. Schiff W M., Hwang J C., Ober M D. et al. Safety and efficacy assessment of chimeric ribozyme to proliferating cell nuclear antigen to prevent recurrence of proliferative vitreoretinopathy. Arch Ophthalmol 2007 125 1161-1167
32. Spitzer M S., Yoeruek E, Kaczmarek R T. et al. Sodium hyaluronate gels as a drug-release system for corticosteroids: release kinetics and antiproliferative potential for glaucoma surgery. Acta Ophthalmol 2008 86 842-848
33. Spitzer M S., Kaczmarek R T., Yoeruek E et al. The distribution, release kinetics, and biocompatibility of triamcinolone injected and dispersed in silicone oil. Invest Ophthalmol Vis Sci 2009 50 2337-2843
34. Szurman P, Kaczmarek R T., Spitzer M S. et al. Differential toxic effect of dissolved triamcinolone and its crystalline deposits on cultured human retinal pigment epithelium (ARPE19) cells. Exp Eye Res 2006 83 584-592
35. Szurman P, Sierra A, Kaczmarek R T. et al. Different biocompatibility of crystalline triamcinolone deposits on retinal cells in vitro and in vivo. Exp Eye Res 2007 85 44-53
36. The Silicone Study Group. Vitrectomy with silicone oil or perfluoropropane gas in eyes with severe proliferative vitreoretinopathy: results of a randomized clinical trial. Arch Ophthalmol 1992 110 780-792
37. Ungphaiboon S, Nittayananta W, Vuddhakul V et al. Formulation and efficacy of triamcinolone acetonide mouthwash for treating oral lichen planus. Am J Health Syst Pharm 2005 62 485-491
38. Wickham L, Bunce C, Wong D et al. Randomized controlled trial of combined 5-Fluorouracil and low-molecular-weight heparin in the management of unselected rhegmatogenous retinal detachments undergoing primary vitrectomy. Ophthalmology 2007 114 698-704
39. Wiedemann P, Hilgers R D., Bauer P et al. Adjunctive Daunorubicin in the treatment of proliferative vitreoretinopathy: results of a multicenter clinical trial. Am J Ophthalmol 1998 126 550-559
40. Williams R G., Chang S, Comaratta M R. et al. Does the presence of heparin and dexamethasone in the vitrectomy infusate reduce reproliferation in proliferative vitreoretinopathy? Graefes Arch Clin Exp Ophthalmol 1996 234 496-503
41. Zhang G, Feng X, Wabner K et al. Intraocular nanoparticle drug delivery: a pilot study using an aerosol during pars plana vitrectomy. Invest Ophthalmol Vis Sci 2007 48 5243-5249